How The Midwest Was Won: Creating A New Epicenter For Device Innovation And Investment

Talent, innovation, world-class research institutions, established supply chains, and a lower cost of doing business – what else do you need to launch and grow a device company? Well, capital, for one. Players in the Midwest are working in a variety of ways to draw entrepreneurs and venture money to the region, and their efforts are reaping positive results.

The American Midwest brings to mind images of vast, fertile fields of wheat, corn, and other important crops, but its significance is now much more than agricultural. The often unassuming US heartland – comprising Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin – is also a fast-growing hotbed for medical device research and development, entrepreneurship, and investment. With industry-leading manufacturers such as Medtronic PLC, St. Jude Medical Inc., Hologic Inc., GE Healthcare/General Electric Co., Cook Group Inc., Boston Scientific Corp., 3M Co., DePuy Orthopaedics Inc./Johnson & Johnson, Biomet Inc., and Zimmer Biomet Holdings Inc. headquartered in the Midwest, the region has long been known for developing and manufacturing a wide variety of advanced implantable devices and imaging technologies. In fact, DePuy, Biomet, and Zimmer alone comprise one-third of the world's orthopedics industry, according to Indiana life sciences accelerator BioCrossroads. And, with its established outsourcing and supply chains, world-class research universities, including Case Western Reserve University and the University of Wisconsin, Madison, a large talent pool, and lower cost of doing business, the Midwest is turning out to be fertile soil indeed for device entrepreneurs launching a new venture.

A critical component for start-up success, however, is financing, and although the Midwest has traditionally been underserved and overlooked by venture capitalists (VCs), the funding picture is improving. In fact, the US heartland is holding increasing appeal for investors and device companies, both those from within the region and those moving in from other areas. To add to this, a burgeoning ecosystem of angel investor groups, early-stage VCs, and state-backed funding programs are helping to support the growing number of innovative device companies starting operations in thriving Midwest cities like Madison, WI, and Cleveland, OH

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Debate On FDA User Fee Reauthorization Begins To Take Shape

 
• By 

A battle may be forming over the 2027 FDA user fee reauthorizations. At a conference Friday, Democratic Rep. Jake Auchincloss supports them for their effectiveness, while Deputy FDA Commissioner Grace Graham echoed criticisms from HHS Sec. Kennedy, among others, in calling for reform to ensure public trust.

More from North America

Health Secretary Defends Spending Cuts During Senate Hearing On HHS Budget

 
• By 

Health and Human Services Secretary Robert F. Kennedy Jr. emphasized administrative cost reductions and defended budget decisions during a Senate hearing on HHS funding. Some senators, however, expressed concerns over the impacts spending cuts had on essential health programs.

Tariffs Threaten Medtech Innovation And US Position As World Leader, Whitaker Tells Lawmakers

 

During his testimony before US senators on the impact of tariffs on critical supply chains, AdvaMed’s Scott Whitaker said the Trump tariffs could jeopardize America’s preeminence in medtech. Other industry experts echoed similar concerns.

Califf Warns Progress May Be In Danger Due To ‘Decimated’ FDA Staff

 

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.